IONS - Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat Midstage Study Data Shows | Benzinga
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH).
The study met its primary endpoint at both doses (120 mg and 90 mg), achieving liver histologic improvement, and also met the important secondary endpoint of MASH resolution.